Metabolic Disorder Therapeutics Market Insights: Global Industry Analysis, Market Drivers, Restraints, Opportunities, Applications, Trends And Forecasts 2020-2026

The Metabolic Disorder Therapeutics Market report offers perceptive information regarding drivers, restraints, opportunities, and trends of the Metabolic Disorder Therapeutics Market. With the use of historic data from (period), the Metabolic Disorder Therapeutics Market report offers Y-o-Y growth and CAGR until 2026. The insightful data offered in the report makes it an invaluable resource for industry executives, marketing, sales and product managers, consultants, analysts and stakeholders that are in search of major industry information in ready-to-access documents with clearly presented tables and graphs.

The global market for Metabolic Disorder Therapeutics Market is expected to witness a CAGR of xx% over the forecast period 2020-2026 and is expected to reach US$ xx million in 2026, from US$ xx million in 2020.

The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers.

The key manufacturers in this market include

  • Novo Nordisk A/S
  • Sanofi S.A.
  • Boehringer Ingelheim GmbH
  • Eli Lilly and Company
  • Merck KgaA
  • Amgen, Inc.
  • AstraZeneca PLC
  • Actelion Pharmaceuticals Ltd.
  • Shire PLC
  • AbbVie, Inc.
  • Biocon Ltd.
  • BioMarin Pharmaceutical, Inc.
  • Bristol-Myers Squibb Company
  • Cipla, Inc.
  • CymaBay Therapeutics, Inc.

On the basis of region, the market is divided into:

  • North America (U.S. and Canada)
  • Latin America (Brazil, Mexico, Argentina, Columbia, and Rest of Latin America)
  • Europe (Germany, the U.K., France, Russia, Italy, and Rest of Europe)
  • Asia Pacific (China, Japan, South Korea, India, Southeast Asia, and Rest of Asia Pacific)
  • Middle East (Saudi Arabia, UAE, Egypt, and Rest of Middle East)
  • Africa (North Africa, Central Africa, and South Africa)

By the product type, the market is primarily segmented into

  • Lysosomal Storage Diseases
  • Diabetes
  • Obesity
  • Inherited Metabolic Disorders
  • Hypercholesterolemia
  • Market segment by Application, split into
  • Oral
  • Parenteral
  • Others

By the End-user Applications, the market is primarily segmented into

  • Oral
  • Parenteral
  • Others

We can also provide the customized separate regional or country-level reports, for the following regions:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Philippines
    • Vietnam
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Russia
  • Central & South America
    • Brazil
  • Middle East & Africa
    • Turkey
    • GCC Countries
    • Egypt
    • South Africa

Key Highlights of the Report:

  • Growth opportunities in the global Metabolic Disorder Therapeutics Market across major regions during the forecast period.
  • Role of emerging markets in the global Metabolic Disorder Therapeutics Market and the scenario during the 2020-2026.
  • Technological and product developments that influence growth of the market.
  • New trends and advancements in the global Metabolic Disorder Therapeutics Market.
  • Insight on various product types and their respective market shares in the overall market.

The report offers you perceptive data of the market and highlights its commercial landscape and pivotal factors that propel and hinder the market growth. It also evaluates production processes, major bottlenecks, and solutions to reduce risks associated with R&D and focuses on major growth strategies adopted by leading market players. The report accurately projects the global market value and regional share during the forecast period

For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Key Stakeholders

  • Raw material suppliers
  • Distributors/traders/wholesalers/suppliers
  • Regulatory bodies, including government agencies and NGO
  • Commercial research & development (R&D) institutions
  • Importers and exporters
  • Government organizations, research organizations, and consulting firms
  • Trade associations and industry bodies
  • End-use industries

Available Customizations

At Worldwide Market Reports we offer tailored researches to help our clients stay ahead in competition.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Metabolic Disorder Therapeutics Revenue
1.4 Market Analysis by Type
1.4.1 Global Metabolic Disorder Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Lysosomal Storage Diseases
1.4.3 Diabetes
1.4.4 Obesity
1.4.5 Inherited Metabolic Disorders
1.4.6 Hypercholesterolemia
1.5 Market by Application
1.5.1 Global Metabolic Disorder Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Oral
1.5.3 Parenteral
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends by Regions
2.1 Metabolic Disorder Therapeutics Market Perspective (2015-2026)
2.2 Metabolic Disorder Therapeutics Growth Trends by Regions
2.2.1 Metabolic Disorder Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Metabolic Disorder Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Metabolic Disorder Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porters Five Forces Analysis
2.3.5 Metabolic Disorder Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Metabolic Disorder Therapeutics Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Metabolic Disorder Therapeutics Players by Market Size
3.1.1 Global Top Metabolic Disorder Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Metabolic Disorder Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Metabolic Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Metabolic Disorder Therapeutics Market Concentration Ratio
3.2.1 Global Metabolic Disorder Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Metabolic Disorder Therapeutics Revenue in 2019
3.3 Metabolic Disorder Therapeutics Key Players Head office and Area Served
3.4 Key Players Metabolic Disorder Therapeutics Product Solution and Service
3.5 Date of Enter into Metabolic Disorder Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)
4.1 Global Metabolic Disorder Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Metabolic Disorder Therapeutics Forecasted Market Size by Type (2021-2026)

5 Metabolic Disorder Therapeutics Breakdown Data by Application (2015-2026)
5.1 Global Metabolic Disorder Therapeutics Market Size by Application (2015-2020)
5.2 Global Metabolic Disorder Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Metabolic Disorder Therapeutics Market Size (2015-2020)
6.2 Metabolic Disorder Therapeutics Key Players in North America (2019-2020)
6.3 North America Metabolic Disorder Therapeutics Market Size by Type (2015-2020)
6.4 North America Metabolic Disorder Therapeutics Market Size by Application (2015-2020)

7 Europe
7.1 Europe Metabolic Disorder Therapeutics Market Size (2015-2020)
7.2 Metabolic Disorder Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Metabolic Disorder Therapeutics Market Size by Type (2015-2020)
7.4 Europe Metabolic Disorder Therapeutics Market Size by Application (2015-2020)

8 China
8.1 China Metabolic Disorder Therapeutics Market Size (2015-2020)
8.2 Metabolic Disorder Therapeutics Key Players in China (2019-2020)
8.3 China Metabolic Disorder Therapeutics Market Size by Type (2015-2020)
8.4 China Metabolic Disorder Therapeutics Market Size by Application (2015-2020)

9 Japan
9.1 Japan Metabolic Disorder Therapeutics Market Size (2015-2020)
9.2 Metabolic Disorder Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Metabolic Disorder Therapeutics Market Size by Type (2015-2020)
9.4 Japan Metabolic Disorder Therapeutics Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Metabolic Disorder Therapeutics Market Size (2015-2020)
10.2 Metabolic Disorder Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Metabolic Disorder Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Metabolic Disorder Therapeutics Market Size by Application (2015-2020)

11 India
11.1 India Metabolic Disorder Therapeutics Market Size (2015-2020)
11.2 Metabolic Disorder Therapeutics Key Players in India (2019-2020)
11.3 India Metabolic Disorder Therapeutics Market Size by Type (2015-2020)
11.4 India Metabolic Disorder Therapeutics Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Metabolic Disorder Therapeutics Market Size (2015-2020)
12.2 Metabolic Disorder Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Metabolic Disorder Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Metabolic Disorder Therapeutics Market Size by Application (2015-2020)

13Key Players Profiles
13.1 Novo Nordisk A/S
13.1.1 Novo Nordisk A/S Company Details
13.1.2 Novo Nordisk A/S Business Overview and Its Total Revenue
13.1.3 Novo Nordisk A/S Metabolic Disorder Therapeutics Introduction
13.1.4 Novo Nordisk A/S Revenue in Metabolic Disorder Therapeutics Business (2015-2020))
13.1.5 Novo Nordisk A/S Recent Development
13.2 Sanofi S.A.
13.2.1 Sanofi S.A. Company Details
13.2.2 Sanofi S.A. Business Overview and Its Total Revenue
13.2.3 Sanofi S.A. Metabolic Disorder Therapeutics Introduction
13.2.4 Sanofi S.A. Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
13.2.5 Sanofi S.A. Recent Development
13.3 Boehringer Ingelheim GmbH
13.3.1 Boehringer Ingelheim GmbH Company Details
13.3.2 Boehringer Ingelheim GmbH Business Overview and Its Total Revenue
13.3.3 Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Introduction
13.3.4 Boehringer Ingelheim GmbH Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
13.3.5 Boehringer Ingelheim GmbH Recent Development
13.4 Eli Lilly and Company
13.4.1 Eli Lilly and Company Company Details
13.4.2 Eli Lilly and Company Business Overview and Its Total Revenue
13.4.3 Eli Lilly and Company Metabolic Disorder Therapeutics Introduction
13.4.4 Eli Lilly and Company Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
13.4.5 Eli Lilly and Company Recent Development
13.5 Merck KgaA
13.5.1 Merck KgaA Company Details
13.5.2 Merck KgaA Business Overview and Its Total Revenue
13.5.3 Merck KgaA Metabolic Disorder Therapeutics Introduction
13.5.4 Merck KgaA Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
13.5.5 Merck KgaA Recent Development
13.6 Amgen, Inc.
13.6.1 Amgen, Inc. Company Details
13.6.2 Amgen, Inc. Business Overview and Its Total Revenue
13.6.3 Amgen, Inc. Metabolic Disorder Therapeutics Introduction
13.6.4 Amgen, Inc. Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
13.6.5 Amgen, Inc. Recent Development
13.7 AstraZeneca PLC
13.7.1 AstraZeneca PLC Company Details
13.7.2 AstraZeneca PLC Business Overview and Its Total Revenue
13.7.3 AstraZeneca PLC Metabolic Disorder Therapeutics Introduction
13.7.4 AstraZeneca PLC Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
13.7.5 AstraZeneca PLC Recent Development
13.8 Actelion Pharmaceuticals Ltd.
13.8.1 Actelion Pharmaceuticals Ltd. Company Details
13.8.2 Actelion Pharmaceuticals Ltd. Business Overview and Its Total Revenue
13.8.3 Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Introduction
13.8.4 Actelion Pharmaceuticals Ltd. Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
13.8.5 Actelion Pharmaceuticals Ltd. Recent Development
13.9 Shire PLC
13.9.1 Shire PLC Company Details
13.9.2 Shire PLC Business Overview and Its Total Revenue
13.9.3 Shire PLC Metabolic Disorder Therapeutics Introduction
13.9.4 Shire PLC Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
13.9.5 Shire PLC Recent Development
13.10 AbbVie, Inc.
13.10.1 AbbVie, Inc. Company Details
13.10.2 AbbVie, Inc. Business Overview and Its Total Revenue
13.10.3 AbbVie, Inc. Metabolic Disorder Therapeutics Introduction
13.10.4 AbbVie, Inc. Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
13.10.5 AbbVie, Inc. Recent Development
13.11 Biocon Ltd.
10.11.1 Biocon Ltd. Company Details
10.11.2 Biocon Ltd. Business Overview and Its Total Revenue
10.11.3 Biocon Ltd. Metabolic Disorder Therapeutics Introduction
10.11.4 Biocon Ltd. Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
10.11.5 Biocon Ltd. Recent Development
13.12 BioMarin Pharmaceutical, Inc.
10.12.1 BioMarin Pharmaceutical, Inc. Company Details
10.12.2 BioMarin Pharmaceutical, Inc. Business Overview and Its Total Revenue
10.12.3 BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Introduction
10.12.4 BioMarin Pharmaceutical, Inc. Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
10.12.5 BioMarin Pharmaceutical, Inc. Recent Development
13.13 Bristol-Myers Squibb Company
10.13.1 Bristol-Myers Squibb Company Company Details
10.13.2 Bristol-Myers Squibb Company Business Overview and Its Total Revenue
10.13.3 Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Introduction
10.13.4 Bristol-Myers Squibb Company Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
10.13.5 Bristol-Myers Squibb Company Recent Development
13.14 Cipla, Inc.
10.14.1 Cipla, Inc. Company Details
10.14.2 Cipla, Inc. Business Overview and Its Total Revenue
10.14.3 Cipla, Inc. Metabolic Disorder Therapeutics Introduction
10.14.4 Cipla, Inc. Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
10.14.5 Cipla, Inc. Recent Development
13.15 CymaBay Therapeutics, Inc.
10.15.1 CymaBay Therapeutics, Inc. Company Details
10.15.2 CymaBay Therapeutics, Inc. Business Overview and Its Total Revenue
10.15.3 CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Introduction
10.15.4 CymaBay Therapeutics, Inc. Revenue in Metabolic Disorder Therapeutics Business (2015-2020)
10.15.5 CymaBay Therapeutics, Inc. Recent Development

14Analyst's Viewpoints/Conclusions

15Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Table
List of Tables

Table 1. Metabolic Disorder Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Metabolic Disorder Therapeutics Revenue
Table 3. Ranking of Global Top Metabolic Disorder Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Metabolic Disorder Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Lysosomal Storage Diseases
Table 6. Key Players of Diabetes
Table 7. Key Players of Obesity
Table 8. Key Players of Inherited Metabolic Disorders
Table 9. Key Players of Hypercholesterolemia
Table 10. Global Metabolic Disorder Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 11. Global Metabolic Disorder Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 12. Global Metabolic Disorder Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 13. Global Metabolic Disorder Therapeutics Market Share by Regions (2015-2020)
Table 14. Global Metabolic Disorder Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 15. Global Metabolic Disorder Therapeutics Market Share by Regions (2021-2026)
Table 16. Market Top Trends
Table 17. Key Drivers: Impact Analysis
Table 18. Key Challenges
Table 19. Metabolic Disorder Therapeutics Market Growth Strategy
Table 20. Main Points Interviewed from Key Metabolic Disorder Therapeutics Players
Table 21. Global Metabolic Disorder Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 22. Global Metabolic Disorder Therapeutics Market Share by Players (2015-2020)
Table 23. Global Top Metabolic Disorder Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Metabolic Disorder Therapeutics as of 2019)
Table 24. Global Metabolic Disorder Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Metabolic Disorder Therapeutics Product Solution and Service
Table 27. Date of Enter into Metabolic Disorder Therapeutics Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Metabolic Disorder Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 30. Global Metabolic Disorder Therapeutics Market Size Share by Type (2015-2020)
Table 31. Global Metabolic Disorder Therapeutics Revenue Market Share by Type (2021-2026)
Table 32. Global Metabolic Disorder Therapeutics Market Size Share by Application (2015-2020)
Table 33. Global Metabolic Disorder Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 34. Global Metabolic Disorder Therapeutics Market Size Share by Application (2021-2026)
Table 35. North America Key Players Metabolic Disorder Therapeutics Revenue (2019-2020) (Million US$)
Table 36. North America Key Players Metabolic Disorder Therapeutics Market Share (2019-2020)
Table 37. North America Metabolic Disorder Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 38. North America Metabolic Disorder Therapeutics Market Share by Type (2015-2020)
Table 39. North America Metabolic Disorder Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 40. North America Metabolic Disorder Therapeutics Market Share by Application (2015-2020)
Table 41. Europe Key Players Metabolic Disorder Therapeutics Revenue (2019-2020) (Million US$)
Table 42. Europe Key Players Metabolic Disorder Therapeutics Market Share (2019-2020)
Table 43. Europe Metabolic Disorder Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 44. Europe Metabolic Disorder Therapeutics Market Share by Type (2015-2020)
Table 45. Europe Metabolic Disorder Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 46. Europe Metabolic Disorder Therapeutics Market Share by Application (2015-2020)
Table 47. China Key Players Metabolic Disorder Therapeutics Revenue (2019-2020) (Million US$)
Table 48. China Key Players Metabolic Disorder Therapeutics Market Share (2019-2020)
Table 49. China Metabolic Disorder Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 50. China Metabolic Disorder Therapeutics Market Share by Type (2015-2020)
Table 51. China Metabolic Disorder Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 52. China Metabolic Disorder Therapeutics Market Share by Application (2015-2020)
Table 53. Japan Key Players Metabolic Disorder Therapeutics Revenue (2019-2020) (Million US$)
Table 54. Japan Key Players Metabolic Disorder Therapeutics Market Share (2019-2020)
Table 55. Japan Metabolic Disorder Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 56. Japan Metabolic Disorder Therapeutics Market Share by Type (2015-2020)
Table 57. Japan Metabolic Disorder Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 58. Japan Metabolic Disorder Therapeutics Market Share by Application (2015-2020)
Table 59. Southeast Asia Key Players Metabolic Disorder Therapeutics Revenue (2019-2020) (Million US$)
Table 60. Southeast Asia Key Players Metabolic Disorder Therapeutics Market Share (2019-2020)
Table 61. Southeast Asia Metabolic Disorder Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 62. Southeast Asia Metabolic Disorder Therapeutics Market Share by Type (2015-2020)
Table 63. Southeast Asia Metabolic Disorder Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 64. Southeast Asia Metabolic Disorder Therapeutics Market Share by Application (2015-2020)
Table 65. India Key Players Metabolic Disorder Therapeutics Revenue (2019-2020) (Million US$)
Table 66. India Key Players Metabolic Disorder Therapeutics Market Share (2019-2020)
Table 67. India Metabolic Disorder Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 68. India Metabolic Disorder Therapeutics Market Share by Type (2015-2020)
Table 69. India Metabolic Disorder Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 70. India Metabolic Disorder Therapeutics Market Share by Application (2015-2020)
Table 71. Central & South America Key Players Metabolic Disorder Therapeutics Revenue (2019-2020) (Million US$)
Table 72. Central & South America Key Players Metabolic Disorder Therapeutics Market Share (2019-2020)
Table 73. Central & South America Metabolic Disorder Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 74. Central & South America Metabolic Disorder Therapeutics Market Share by Type (2015-2020)
Table 75. Central & South America Metabolic Disorder Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 76. Central & South America Metabolic Disorder Therapeutics Market Share by Application (2015-2020)
Table 77. Novo Nordisk A/S Company Details
Table 78. Novo Nordisk A/S Business Overview
Table 79. Novo Nordisk A/S Product
Table 80. Novo Nordisk A/S Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US$)
Table 81. Novo Nordisk A/S Recent Development
Table 82. Sanofi S.A. Company Details
Table 83. Sanofi S.A. Business Overview
Table 84. Sanofi S.A. Product
Table 85. Sanofi S.A. Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US$)
Table 86. Sanofi S.A. Recent Development
Table 87. Boehringer Ingelheim GmbH Company Details
Table 88. Boehringer Ingelheim GmbH Business Overview
Table 89. Boehringer Ingelheim GmbH Product
Table 90. Boehringer Ingelheim GmbH Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US$)
Table 91. Boehringer Ingelheim GmbH Recent Development
Table 92. Eli Lilly and Company Company Details
Table 93. Eli Lilly and Company Business Overview
Table 94. Eli Lilly and Company Product
Table 95. Eli Lilly and Company Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US$)
Table 96. Eli Lilly and Company Recent Development
Table 97. Merck KgaA Company Details
Table 98. Merck KgaA Business Overview
Table 99. Merck KgaA Product
Table 100. Merck KgaA Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US$)
Table 101. Merck KgaA Recent Development
Table 102. Amgen, Inc. Company Details
Table 103. Amgen, Inc. Business Overview
Table 104. Amgen, Inc. Product
Table 105. Amgen, Inc. Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US$)
Table 106. Amgen, Inc. Recent Development
Table 107. AstraZeneca PLC Company Details
Table 108. AstraZeneca PLC Business Overview
Table 109. AstraZeneca PLC Product
Table 110. AstraZeneca PLC Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US$)
Table 111. AstraZeneca PLC Recent Development
Table 112. Actelion Pharmaceuticals Ltd. Business Overview
Table 113. Actelion Pharmaceuticals Ltd. Product
Table 114. Actelion Pharmaceuticals Ltd. Company Details
Table 115. Actelion Pharmaceuticals Ltd. Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US$)
Table 116. Actelion Pharmaceuticals Ltd. Recent Development
Table 117. Shire PLC Company Details
Table 118. Shire PLC Business Overview
Table 119. Shire PLC Product
Table 120. Shire PLC Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US$)
Table 121. Shire PLC Recent Development
Table 122. AbbVie, Inc. Company Details
Table 123. AbbVie, Inc. Business Overview
Table 124. AbbVie, Inc. Product
Table 125. AbbVie, Inc. Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US$)
Table 126. AbbVie, Inc. Recent Development
Table 127. Biocon Ltd. Company Details
Table 128. Biocon Ltd. Business Overview
Table 129. Biocon Ltd. Product
Table 130. Biocon Ltd. Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US$)
Table 131. Biocon Ltd. Recent Development
Table 132. BioMarin Pharmaceutical, Inc. Company Details
Table 133. BioMarin Pharmaceutical, Inc. Business Overview
Table 134. BioMarin Pharmaceutical, Inc. Product
Table 135. BioMarin Pharmaceutical, Inc. Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US$)
Table 136. BioMarin Pharmaceutical, Inc. Recent Development
Table 137. Bristol-Myers Squibb Company Company Details
Table 138. Bristol-Myers Squibb Company Business Overview
Table 139. Bristol-Myers Squibb Company Product
Table 140. Bristol-Myers Squibb Company Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US$)
Table 141. Bristol-Myers Squibb Company Recent Development
Table 142. Cipla, Inc. Company Details
Table 143. Cipla, Inc. Business Overview
Table 144. Cipla, Inc. Product
Table 145. Cipla, Inc. Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US$)
Table 146. Cipla, Inc. Recent Development
Table 147. CymaBay Therapeutics, Inc. Company Details
Table 148. CymaBay Therapeutics, Inc. Business Overview
Table 149. CymaBay Therapeutics, Inc. Product
Table 150. CymaBay Therapeutics, Inc. Revenue in Metabolic Disorder Therapeutics Business (2015-2020) (Million US$)
Table 151. CymaBay Therapeutics, Inc. Recent Development
Table 152. Research Programs/Design for This Report
Table 153. Key Data Information from Secondary Sources
Table 154. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Metabolic Disorder Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Lysosomal Storage Diseases Features
Figure 3. Diabetes Features
Figure 4. Obesity Features
Figure 5. Inherited Metabolic Disorders Features
Figure 6. Hypercholesterolemia Features
Figure 7. Global Metabolic Disorder Therapeutics Market Share by Application: 2020 VS 2026
Figure 8. Oral Case Studies
Figure 9. Parenteral Case Studies
Figure 10. Others Case Studies
Figure 11. Metabolic Disorder Therapeutics Report Years Considered
Figure 12. Global Metabolic Disorder Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Metabolic Disorder Therapeutics Market Share by Regions: 2020 VS 2026
Figure 14. Global Metabolic Disorder Therapeutics Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Metabolic Disorder Therapeutics Market Share by Players in 2019
Figure 17. Global Top Metabolic Disorder Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Metabolic Disorder Therapeutics as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Metabolic Disorder Therapeutics Revenue in 2019
Figure 19. North America Metabolic Disorder Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Metabolic Disorder Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Metabolic Disorder Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Metabolic Disorder Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Metabolic Disorder Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Metabolic Disorder Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Metabolic Disorder Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Novo Nordisk A/S Total Revenue (US$ Million): 2019 Compared with 2018
Figure 27. Novo Nordisk A/S Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)
Figure 28. Sanofi S.A. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Sanofi S.A. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)
Figure 30. Boehringer Ingelheim GmbH Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Boehringer Ingelheim GmbH Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)
Figure 32. Eli Lilly and Company Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Eli Lilly and Company Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)
Figure 34. Merck KgaA Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Merck KgaA Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)
Figure 36. Amgen, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Amgen, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)
Figure 38. AstraZeneca PLC Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. AstraZeneca PLC Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)
Figure 40. Actelion Pharmaceuticals Ltd. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. Actelion Pharmaceuticals Ltd. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)
Figure 42. Shire PLC Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. Shire PLC Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)
Figure 44. AbbVie, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 45. AbbVie, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)
Figure 46. Biocon Ltd. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 47. Biocon Ltd. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)
Figure 48. BioMarin Pharmaceutical, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 49. BioMarin Pharmaceutical, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)
Figure 50. Bristol-Myers Squibb Company Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. Bristol-Myers Squibb Company Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)
Figure 52. Cipla, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Cipla, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)
Figure 54. CymaBay Therapeutics, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. CymaBay Therapeutics, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2015-2020)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed

Choose License Type

Happy To Assist You

Contact Images

We will be happy to help you find what you need. Please call us or write to us:

Frequently Asked Questions

This report incorporates the analysis of factors that augments the market growth. Report presents competitive landscape of the global market. This also provides the scope of different segments and applications that can potentially influence the market in the future. The analysis is based on current market trends and historic growth data. It includes detailed market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast. The market was valued at xxx Million US$ in 2019, and is expected to grow at a CAGR of xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the industry in terms of Value (US$ Mn) and Volume (Thousands Units).
Market is segmented by:
  • Product Types
  • Drug Class
  • Indication
  • Applications
  • Services Types
  • End-users
  • Distribution channel
  • Regions
The report share key insights on the following:
  • Current market size
  • Market forecast
  • Market opportunities
  • Key drivers
  • Restraints
  • Pipeline Analysis
  • Incidence Rate
  • Epidemiology Analysis
  • Prevalence rate
  • Regulatory scenario
  • Industry trend
  • Pestle Analysis
  • Porter’s Analysis
  • New product approvals/launch
  • Promotion and marketing initiatives
  • Pricing analysis
  • Export-import analysis
  • Trade analysis
  • Competitive landscape
It helps the businesses in making investments decisions.
Customization helps the organization to gain insight on specific segments and regions of interest. Thus, WMR offers tailored report information based on business requirement in order to take strategic calls.
Contact us

mapicon
Sales Office (U.S.):
Worldwide Market Reports, 1001 4th Ave, #3200 Seattle, WA 98154, U.S.

mapicon+1-415-871-0703

mapicon
Asia Pacific Intelligence Center (India):
Worldwide Market Reports 203, 2nd Floor, Bremen Business Center, Aundh, Pune, Maharashtra 411007, India.

Newsletter

Want us to send you latest updates of the current trends, insights, and more, signup to our newsletter (for alerts, special offers, and discounts).

Secure Payment By:
paymenticon

This website is secured Origin CA certificate on the server, Comodo, Firewall and Verified Sitelock Malware Protection

secureimg

© 2020 Worldwide Market Reports. All rights reserved